CD274 and neoplasm: Programmed death-ligand 1 blockade using therapeutic anti-PD-L1 antibodies is a promising approach in the therapy of a variety of cancers as it interferes with a co-inhibitory checkpoint pathway on TILs and thereby enhances anti-tumor immunity (1).